Published by
@ShahidNShah
@ShahidNShah
January 30 to February 1, 2023
Exploit Understanding of TGF-β Biology, Harness Clinically Validated Biomarkers & Advance Safe & Efficacious Clinical Programs for Maximal Therapeutics Benefit in Immuno-Oncology.
In the past year alone, the field has learnt valuable lessons from the clinical trials and from the wider TGF-β field that will equip the immuno-oncology field with the knowledge needed to supercharge future TGF-β monotherapy or combinational therapeutics for precision medicine.
From uncovering the effects and production of TGF-β in immune, tumor and stromal cells to exploring predictive and pharmacodynamic TGF-β biomarkers for patient identification and assessing the clinical challenges that led to recent clinical failures, the 3rd TGF-β for Immuno-Oncology Drug Development Summit is your one-stop-shop dedicated to harnessing you with the knowledge to unlock the potential of successfully targeting TGF-β.
Tailored with 18+ senior leaders, the 2023 meeting will be taking place in-person for the first time - don't miss your chance to be in the room for your comprehensive guide on TGF-β in immuno-oncology!
Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from the basic biology to biomarkers to clinical trial design to overcome the clinical setbacks and produce a blockbuster TGF-β therapeutic.
Continue reading at tgf-beta-summit.com
January 30 to February 1, 2023
Marines' Memorial Club & Hotel, 609 Sutter Street, San Francisco, California, 94102, United States
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2024 Netspective Foundation, Inc. All Rights Reserved.
Built on Nov 15, 2024 at 12:42pm